Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · The Lancet Infectious Diseases · 2020 · 1.5K citations · Full text

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanrıöver, Levent Doğanay, Murat Akova et al. · The Lancet · 2021 · 922 citations · Full text

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

The Lancet · 2021 · 673 citations · Full text

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens, Lily Yin Weckx, Ralf Clemens et al. · The Lancet · 2022 · 461 citations · Full text

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros‐Martins, Swantje I. Hammerschmidt, Anne Cossmann et al. · Nature Medicine · 2021 · 455 citations · Full text